Effectivity of Long-Acting Injectable Antipsychotics Use In Schizophrenia Patients: A Literature Study


  • Nanda Restiana Medical Faculty, Lampung University
  • Dwi Aulia Ramdini Medicinal Faculty Lampung University
  • Ramadhan Triyandi Medicinal Faculty Lampung University




effectivity, decanoate, injectable, schizophrenia


Schizophrenia is a complex syndrome with a heterogeneous combination of symptoms that can be divided into positive, negative and cognitive symptoms. Based on data from the World Health Organization (WHO) in 2019 the prevalence of schizophrenia worldwide affects around 24 million people or 1 in 300 people with a proportion of 0.32%. The main pharmacological treatment for schizophrenia is antipsychotic drugs. Classification of antipsychotics is divided into two, namely first generation antipsychotics which are known as typical or conventional and second generation antipsychotics which are known as atypical or non conventional antipsychotics. Estimates of the discontinuation rate for oral antipsychotics range from 26 to 44%, leading to symptomatic recurrence as well as an increased risk of hospitalization. Long-acting injectable antipsychotics were developed to address this problem and have been shown to be more effective than oral antipsychotics in preventing relapse and treating them. The purpose of writing this article is to describe the effectiveness of long-term injectable antipsychotic use in schizophrenic patients. The library search method is carried out online using electronic databases, namely Pubmed NCBI and Google Scholar. Long-acting injectable antipsychotics namely risperidone, paliperidone palmitate, fluphenazine decanoate, and flupentixol decanoate were effective in being used in schizophrenic patients to reduce the severity of symptoms as seen from the Positive and Negative Syndrome Scale (PANSS) score, recurrence and risk of hospitalization.


Kahn RS, Sommer IE, Murray RM, Lindenberg AM, Weinberger RM, Cannon TD, Dkk. Schizophrenia. Nat Rev Dis Primers. 2015;1(15): 67.

Elvira SD, Hadisukanto G. Buku ajar psikiatri. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2013.

WHO. Schizophrenia. America: World Health Organization; 2022.

Kemenkes RI. Situasi Kesehatan Jiwa Di Indonesia Pusat Data dan Informasi. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019

Hany M, Rehman B, Chapman J. Schizophrenia. America: StatPearls Publishing; 2019.

Lally J, Gaughran F, Timms P, Curran SR. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics Pers Med. 2016;9 (1):117-129.

Correll CU, Kim E, Sliwa JK, Hamm W. Gopal S. Mathews M. Dkk. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs. 2021;35(1):39-59.

Kishimoto T, Robenzadeh A, Leucht C, Watanabe K, Mimura M, Kane JM, Dkk. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.

Deng C, Dean B. Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathways. Front Cell Neurosci. 2013;7(2):238.

Kaplan HI, Saddock BJ, Grabb J. Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th edn. Philadelphia: Lippincott Williams and Wilkins and Wolter Kluwer Health.

Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7(2):1171-1180.

Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198-219.

Alphs L, Bossie C, Mao L, Lee E, Starr HL. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. Early Interv Psychiatry. 2018;12(1):55-65.

Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznano NG, dkk. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1-3):393-399.

Yu HY, Hsiao CY, Chen KC, Lee LT, Chang WH, Chi MH, Dkk. A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study. Schizophr Res. 2015;169(1-3):400-405.

Malla A, Chue P, Jordan G, Stip E, Koczerginski D, Milliken H, Dkk. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses. 2016;9(4):198-208.

Zhang F, Si T, Chiou CF, Harris AW, Kim CY, Jahagirdar P, Dkk. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11(1):657-668.

McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial [published correction appears in JAMA. 2014 Oct 8;312(14):1473]. JAMA. 2014;311(19):1978-1987.

Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Dkk. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;(2):307.

Chiliza B, Asmal L, Emsley R. A prospective study of clinical, biological and functional aspects of outcome in first-episode psychosis: The EONKCS Study. South African Journal of Psychiatry. 2015; 21 (3):109.

Olivier MR, Killian S, Chiliza B, Asmal L, Schoeman R, Oosthuizen P, Dkk. Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study. Psychol Med. 2015;45(13):2873-2883.



How to Cite

Restiana, N., Ramdini, D. A., & Triyandi, R. (2023). Effectivity of Long-Acting Injectable Antipsychotics Use In Schizophrenia Patients: A Literature Study. Medical Profession Journal of Lampung, 13(4), 521-526. https://doi.org/10.53089/medula.v13i4.753




Most read articles by the same author(s)

1 2 > >>